Fluoxetine is one of the most commonly prescribed antidepressants in the selective serotonin reuptake inhibitor (SSRI) class. Epidemiologic studies have suggested a link between maternal fluoxetine use during pregnancy and an increased incidence of birth defects. However, the mechanisms by which fluoxetine adversely impacts embryonic developments are unknown. Here, we used the mouse P19C5 embryoid body (EB) as a 3D morphogenesis model to investigate the developmental toxicity of fluoxetine. Morphological and molecular changes in P19C5 EBs replicate the processes of axial elongation and patterning seen in early embryos, and these changes are specifically and sensitively altered by exposure to developmental toxicants. Treatment with fluoxetine, or its major metabolite, norfluoxetine, adversely affected EB morphogenesis at concentrations of 6 mM and above. Treatment with other serotonin reuptake inhibitors or serotonin itself did not impair EB morphogenesis, suggesting that the adverse effects of fluoxetine are independent of serotonin signaling. Gene expression analyses showed that various key developmental regulators were affected by fluoxetine, particularly those involved in mesodermal differentiation. Reporter assays demonstrated that fluoxetine inhibited canonical Wnt signaling, and that the pharmacologic activation of canonical Wnt signaling partially alleviated the morphogenetic effects of fluoxetine. Fluoxetine also exhibited cytostatic effects independently of inhibition of the serotonin transporter or canonical Wnt signaling. These results suggest that the SSRI-independent actions of fluoxetine, namely inhibition of canonical Wnt signaling and reduction of cellular proliferation, are largely responsible for the observed adverse morphogenetic impacts. This study provides mechanistic insight for further investigations on the teratogenicity of fluoxetine.
likely to cause harm if used during pregnancy. This understanding can only be obtained through continued investigations on the developmental toxicity of antidepressants using retrospective human epidemiologic studies as well as more prospective and mechanistic analyses using animal and in vitro models. With such information, clinicians can differentiate various types of antidepressants based on their relative safety for use during pregnancy and prescribe the safest medications to the patients.
Fluoxetine (a.k.a. Prozac) is one of the most commonly prescribed antidepressants of the selective serotonin reuptake inhibitor (SSRI) class (Sommi et al., 1987) . By inhibiting the serotonin transporter (SERT; encoded by the SLC6A4 gene), fluoxetine and other SSRIs increase the synaptic levels of serotonin (5-hydroxytryptamine or 5-HT), a monoamine neurotransmitter that helps to regulate mood. Several human epidemiologic studies have identified significant associations between maternal use of fluoxetine during pregnancy and an increased incidence of specific congenital anomalies, such as cardiac defects, pulmonary hypertension, gastroschisis and omphalocele (Diav-Citrin et al., 2008; Ellfolk and Malm, 2010; Malm et al., 2011; Myles et al., 2013; Reefhuis et al., 2015; Wemakor et al., 2015) . Although the link between fluoxetine intake and birth defects is primarily epidemiological and needs further investigations, the drug may potentially impair embryonic development through various mechanisms. For example, fluoxetine may inhibit SERT in the fetus, inhibit SERT in the mother, and/or affect an off-target molecule unrelated to serotonin signaling altogether. In the mouse embryo, SERT is expressed in the heart and liver as early as the E10.5 stage (Narboux-Nême et al., 2008) . Fluoxetine may inhibit SERT in these embryonic tissues to directly cause organ malformations (Sadler, 2011) . Alternatively, the developmental toxicity of fluoxetine may be indirect if it acts on SERT in the pregnant mother, altering maternal physiology (eg, decreasing placental blood flow) and resulting in adverse effects on embryonic development. For example, fluoxetine causes severe anorexia in rats, leading to maternal starvation with secondary adverse reproductive outcomes (Sloot et al., 2009; Wong et al., 1988) . Finally, fluoxetine may target non-SERT molecules that play essential roles in embryogenesis. In vivo studies with humans or model animals are often too complex to distinguish which of these possibilities is responsible for the teratogenic action of fluoxetine. On the other hand, in vitro tests are devoid of maternal factors and are more amenable to experimental manipulations and molecular analyses. Thus, in vitro models may provide valuable mechanistic insight into the developmental toxicity of fluoxetine.
One such in vitro model uses stem cell-derived embryoid bodies (EBs) capable of spontaneous axial morphogenesis to study the effects of developmental toxicants. These EBs are created from P19C5 mouse stem cells, which possess developmental properties similar to the epiblast, the pluripotent embryonic precursor of the fetal body (Lau and Marikawa, 2014) . P19C5 cells can be aggregated in a hanging drop of culture medium to differentiate as an EB, which transforms from a spherical mass to an elongated structure during 4 days of culture. This morphological transformation is an in vitro recreation of gastrulation, the morphogenetic process of body patterning and elongation along the cranial-caudal embryonic axis. The developmental toxicity of chemical agents can be assessed based on their adverse impact on the in vitro morphogenesis of P19C5 EBs, a model that was recently validated using the Daston list of reference chemical exposures (Daston et al., 2014; Warkus and Marikawa, 2017) . The Daston list consists of 39 exposures, ie, in vivo concentrations of specific compounds that cause adverse effects on embryos or lack thereof (Daston et al., 2014) . Growth and morphogenesis of P19C5 EBs were significantly altered by the adverse exposures in the Daston list, but not by the nonadverse exposures, with a total concordance of 71.4%-82.9% (Warkus and Marikawa, 2017) . Thus, the morphogenesis-based P19C5 EB assay can serve as an effective in vitro alternative to evaluate developmental toxicity of compounds at physiologically relevant concentrations. Notably, the P19C5 EB model is distinct from other stem cell-based in vitro assays, particularly those collectively known as embryonic stem cell tests (ESTs), which evaluate the inhibitory effects of chemical exposures on the differentiation of a specific cell type, such as cardiomyocytes, chondrocytes, or neurons (Riebeling et al., 2012; Theunissen and Piersma, 2012) . In contrast to ESTs, the P19C5 EB model assesses chemical impact on 3D morphogenesis, which is regulated by a wide range of cellular activities, such as proliferation, migration, adhesion, and shape change. Misregulation of these cellular activities is closely linked to a variety of common birth defects, such as neural tube closure defects, heart septal closure defects, and cleft lip and palate (Sadler, 2012) . Thus, morphology-based tests using P19C5 EBs may have an advantage over other differentiation-based ESTs in order to evaluate the morphogenetic impact of chemical exposures linked to common birth defects.
The P19C5 EB morphogenesis model is also a useful tool to study the molecular mechanisms of developmental toxicity. During the 4 days of culture, EBs exhibit dynamic gene expression patterns in a distinct temporal manner that is similar to the time course of gene regulation in the in vivo embryo (Lau and Marikawa, 2014; Marikawa, 2015, 2016) (Table 1) . The level and temporal patterns of these gene expressions are regulated by specific molecular signals, namely Wnt, Nodal, Fgf, Bmp, Notch, and retinoic acid, which was demonstrated using pharmacological inhibitors against each of these signaling pathways (Li and Marikawa, 2015) . Disruption of a particular signal in EBs by the inhibitor causes distinct alterations in the gene expression patterns, yielding "disruption profiles" that are specific to each signaling pathway. Comparison of these disruption profiles to the gene expression patterns of EBs exposed to a teratogen can provide mechanistic insight to identify which molecular signals are impacted by the teratogenic exposure. This strategy was demonstrated to be effective in a recent study, which revealed that valproic acid (a well-known teratogen) adversely affects morphogenesis by enhancing retinoic acid signaling (Li and Marikawa, 2016) . Thus, the P19C5 EB platform can serve as a mechanistic alternative to gain insight into how teratogens alter molecular events that are crucial for normal embryogenesis.
In this study, we used the P19C5 EB system to investigate the mechanism of fluoxetine's effects on embryonic morphogenesis, particularly concerning its adverse concentration levels, impact on gene expression profiles, and molecular pathways that are independent of SERT inhibition.
MATERIALS AND METHODS
Compounds. All chemical compounds used in this study were commercially obtained, and their details are described in Table 2 .
Cell culture and EB generation. P19C5 cells were cultured and induced for in vitro morphogenesis, according to the methods described previously in Lau and Marikawa (2014) and Warkus and Marikawa (2017) . Briefly, cells were maintained in the P19 culture medium (Minimum Essential Medium Alpha, nucleosides, GlutaMAX Supplement [LifeTechnologies, Carlsbad, California], 2.5% fetal bovine serum, 7.5% newborn calf serum, 50 U/ml penicillin and 50 lg/ml streptomycin). For EB generation, cells were dissociated with TrypLE Express (LifeTechnologies) and suspended at a density of 10 cells/mL in the culture medium containing a final concentration of 1% (v/v) dimethyl sulfoxide (DMSO) with or without a test compound. Such a high concentration (1%) of DMSO has been used routinely in numerous studies to induce differentiation of P19 mouse embryonal carcinoma cells (the parental line of P19C5), particularly into the mesodermal lineage (Lau and Marikawa, 2014; McBurney, 1993; Skerjanc, 1999) . Droplets (20 ml each) of cell suspension were deposited on the inner surface of Petri dish lids and were cultured for up to 4 days in an incubator with 4.5% CO 2 at 37 C in humidified air. EBs were monitored daily for survival and overall integrity before being harvested for morphometric and gene expression analyses (Figure 1 ) .
Morphometric analyses. Images of EBs were obtained after 4 days of hanging drop culture (day 4) and opened in the ImageJ program (http://rsb.info.nih.gov/ij) for morphometric analyses, as previously described (Warkus and Marikawa, 2017) . Briefly, the outline (perimeter) of individual EBs was automatically identified using a macro and measured to obtain morphometric parameters, such as area and circularity. Area was used to estimate the overall size of EBs, whereas the elongation distortion index (EDI), which is calculated from circularity Temporal expression profiles in unmanipulated (control) P19C5 EBs based on the previous studies (Lau and Marikawa, 2014; Marikawa, 2015, 2016) and this study.
(EDI ¼ 1/circularity À 1), was used to assess the extent of EB axial elongation. Area and EDI were normalized by the average values of control EBs in each set of experiments, and were reported as relative area and relative EDI, respectively, expressed in percentages (the average values of control are 100%). Three sets of experiments were conducted for each treatment condition as biological replicates, and relative area and relative EDI were compiled and presented as mean 6 95% CIs. Adverse morphogenetic effects were defined as a reduction in relative area by >20% and/or a change in relative EDI by >40%, which are thresholds based on the criteria established in the previous validation study (Warkus and Marikawa, 2017) .
Reverse transcription and polymerase chain reaction assays. Total RNA was extracted from cell suspension prior to aggregation (day 0) and from EBs on days 1-4, using TRI reagent (LifeTechnologies) and Direct-zol RNA MiniPrep kit (Zymo Research, Irvine, California), and processed for cDNA synthesis using M-MLV Reverse Transcriptase (Promega, Madison, Wisconsin) and oligodT (18) primer. The preparation of cDNA from the mouse whole embryo was described previously in Li and Marikawa (2015 were resolved in a 1% agarose gel and visualized by staining with ethidium bromide. Note that primers for Slc6a4 (F: 5'-GTT CTG CAG CGA CGT GAA GGA AAT-3', R: 5'-GCT TAG AGG GGA GGA GTC AAG GTG-3') and Slc6a2 (F: 5'-GTG GTG GTC AGC ATC ATC AAC TTC-3', R: 5'-AAC CAG CGT CAC GGA ATC ATT AGT-3') were designed as intron-spanning, so that PCR products amplified from cDNA could be distinguished from those from genomic DNA based on the product size (416 and 520 bp for Slc6a4 and Slc6a2 mRNA, respectively). Quantitative RT-PCR was performed using the CFX96 RealTime PCR Detection System (Bio-Rad, Hercules, California) with SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) as follows: initial denaturation at 94 C for 5 min, followed by up to 45 cycles of 94 C for 15 s, 60 C for 20 s, and 72 C for 40 s. Data files were opened in CFX Manager software (Bio-Rad) and Ct values were transferred to the Excel program for further analyses. Actb, which encodes ß-Actin, was used as a constitutively expressed housekeeping gene to standardize the expression levels of the other genes. Relative expression level was calculated as a percentage relative to the total expression level of control EBs (a sum of days 0-4 values) in each set of experiments. Three sets of experiments were conducted for each treatment condition as biological replicates, and relative expression levels were compiled and presented as mean 6 SD. Luciferase reporter assays. The plasmids used for luciferase reporter assays were obtained commercially or from other researchers. TOPFLASH (Upstate, Charlottesville, Virginia) consists of the firefly luciferase gene controlled by the transcriptional promoter containing multiple TCF-binding sites and serves as a reporter for active canonical Wnt signaling. FOPFLASH (Upstate), used as a negative control for TOPFLASH, contains inactivating mutations in the TCF-binding sites. pRL-TK (Promega) encodes the Renilla luciferase gene under the control of a constitutive promoter (thymidine kinase promoter) and was used to normalize the luciferase activities of TOPFLASH and FOPFLASH. L1CBD-G4DBD encodes a chimeric protein containing the ß-Catenin-binding domain of LEF1 and the DNAbinding domain of GAL4. Like TOPFLASH, L1CBD-G4BD serves as a monitoring tool for active canonical Wnt signaling, as previously described in Tamashiro et al. (2008) . Binding of ß-Catenin to L1CBD-G4DBD forms a transcriptional activator to turn on the expression of the firefly luciferase from pG5-Luc, which contains multiple GAL4-binding sites (Promega). G4DBD, which is GAL4-binding domain without a ß-Catenin domain, was used as a control for L1CBD-G4DBD (Tamashiro et al., 2008) . ARE-Luc (a gift from Dr. Malcolm Whitman; Harvard Medical School) consists of the firefly luciferase controlled by the activin response elements and serves as a reporter for active Nodal/Activin signaling (Weisberg et al., 1998) . P19C5 cells in monolayer were transfected with the plasmids using Lipofectamine 2000 (LifeTechnologies). The final concentration of DMSO was adjusted to 0.1% regardless of the concentration of test compounds. After 24 h, cells were lysed and examined for luciferase activity using the Dual-Luciferase Reporter Assay System (Promega) with Gene Light 55 Luminometer (Microtech, Chiba, Japan). All experiments were repeated independently 3 times. The results are shown as mean 6 SD.
Cell viability assay. Effect of chemical treatment on cell proliferation and viability was determined with the CellTiter-Glo Luminescent Cell Viability Assay System (Promega), as described previously in Warkus et al. (2016) . Briefly, P19C5 cells were seeded in 96-well plates at a density of 100 cells/well in 100 ml of culture medium supplemented with 1% DMSO containing the test compound or vehicle only as a control. After 4 days of culture, cells were treated with CellTiter-Glo Reagent. The resulting luminescence was measured using Gene Light 55 Luminometer as a readout of ATP amount, which serves as a quantitative proxy for the number of metabolically active cells. The intensity of the luminescence was normalized to the control level (vehicle only) in each set of experiments and reported as relative light units. All experiments were repeated independently 3 times, and the results are shown as mean 6 SD.
Statistics. Statistical differences were assessed by 2-sample t test. For EB morphogenesis, relative area and relative EDI were compared between 2 groups of EBs, typically compound-treated EBs and vehicle-treated control EBs (n ¼ 45-48 for each group, compiled from 3 sets of independent experiments), unless otherwise stated. Differences in average values were deemed significant when p values were < .01. For luciferase reporter assays, normalized luciferase activities, ie, ratios of the firefly luciferase to the Renilla luciferase signals, from 3 independent experiments were compared between compound-treated and control (vehicle only) groups. For the cell viability assay, relative light units from 3 independent experiments were compared between compound-treated and control cells.
RESULTS

Fluoxetine Impairs Morphogenesis of P19C5 EBs in a DoseDependent Manner
The teratogenic potential of fluoxetine was evaluated using the P19C5 EB morphogenesis system (Figure 1 ). P19C5 cells were aggregated in hanging drops of culture medium containing various concentrations of fluoxetine, and the morphology of the resulting EBs was examined after 4 days of culture. We focused on a concentration range between 2 and 10 mM, because our pilot study suggested that fluoxetine at 1 mM or less had no morphological impact, whereas fluoxetine concentrations higher than 10 mM were detrimental to the survival of EBs. Treatment effects were quantified using 2 morphometric parameters, the 2D area of EBs, which is a proxy for EB size, and the EDI, which was used to evaluate the extent of axial elongation. Following the previous validation study, morphologic impacts were only considered to be adverse if drug treatment caused a reduction in relative area by >20% or a reduction in relative EDI by >40% compared with control EBs (Warkus and Marikawa, 2017) . EB morphogenesis was adversely affected by fluoxetine treatment at the exposure levels of 6 mM and higher, which reduced both relative area and relative EDI in a dose-dependent manner (Figs. 2A and 2B).
We then evaluated the effects of R-fluoxetine, S-fluoxetine, and norfluoxetine on EB morphogenesis. Fluoxetine is a racemic mixture of R-and S-enantiomers. R-and S-fluoxetine are similar in their potency as serotonin reuptake inhibitors (SSRIs), although the latter (S) is slightly more potent than the former (R) (Gram, 1994; Wong et al., 1995) . Norfluoxetine, the major metabolite of fluoxetine, is a potent SSRI with a longer half-life in the circulating plasma (Hiemke and H€ artter, 2000) . The morphogenetic effects of these compounds were tested at 2, 6, 10, and 20 lM, to match the experiments done with fluoxetine. All the compounds adversely affected EB morphogenesis at 6 lM and higher, although S-fluoxetine appeared slightly less potent than the others with respect to the extent of reduction in area and EDI (Figs. 2C and 2D) . Thus, the morphogenesis of EBs was susceptible to exposures to fluoxetine, its enantiomers, and metabolite with largely similar dose-dependency.
The Morphogenetic Effects of Fluoxetine Is Not Due to Inhibition of SERT
We assessed whether the action as an SSRI is responsible for the adverse morphogenetic effects of fluoxetine. First, expression of the Slc6a4 gene was examined in P19C5 EBs, as it encodes the SERT, the main target of SSRI action. For comparison, expression of the Slc4a2 gene, which encodes the norepinephrine transporter (NET) was also examined, as both SERT and NET are inhibited by antidepressants of the serotonin and norepinephrine reuptake inhibitor (SNRI) class, such as venlafaxine. Both Slc6a4 and Slc6a2 mRNAs were robustly expressed in the mouse embryo at the stage E10.5. Conversely, in P19C5 EBs (as a mixture of days 0-4), only Slc6a2 mRNA was robustly expressed ( Figure 3A) . Quantitative RT-PCR analysis showed that Slc6a2 mRNA was highly expressed only at day 0 (ie, before cell aggregation), and that the expression of Slc6a4 mRNA was very low-<5% of the whole embryo level-at all stages of EBs ( Figure 3B ).
Although the level was very low, the expression of SERT may be sufficient to cause adverse effects in EBs if inhibited by fluoxetine. Thus, we evaluated the morphogenetic impact of other inhibitors of SERT, specifically citalopram (SSRI) and venlafaxine (SNRI). EB morphology was assessed after 4 days of treatment with either citalopram or venlafaxine at 0, 2, 6, 10, or 20 mM. Neither citalopram nor venlafaxine exhibited adverse effects even at the highest concentrations tested (Figs. 3C and  3D ). Since SSRIs elevate the levels of extracellular 5-HT, we also tested the impact of excessive 5-HT on EB morphogenesis. None of the concentrations tested (ranging from 10 to 100 mM) caused adverse morphogenetic effects (Figs. 3E and 3F ). These results indicate that the SSRI action is not responsible for the adverse morphogenetic effects of fluoxetine and suggest that fluoxetine may target molecular mechanisms unrelated to SERT when it interferes with embryonic morphogenesis.
Fluoxetine Alters Expression Patterns of Various Developmental Regulator Genes
To gain mechanistic insight into the morphogenetic effects of fluoxetine, we examined how fluoxetine treatment alters expression patterns of key developmental regulator genes in EBs. EBs were treated with fluoxetine at the concentrations of 0 mM (control), 2 and 6 mM, and harvested at days 0-4 for gene expression analyses by quantitative RT-PCR (Figure 1 ). These concentrations were selected because 2 mM had no morphogenetic impact, whereas 6 mM was the lowest concentration that altered both area and EDI ( Figure 2B ). The developmental regulators examined are transcription factors and signaling molecules that are crucial for embryo patterning and germ layer formation, and their characteristics are summarized in Table 1 .
Fluoxetine at 2 mM did not significantly alter the transcript levels of any of the developmental regulators during EB development ( Figure 4A ). However, fluoxetine at 6 mM changed the expression patterns of a number of genes relative to the patterns in vehicle-treated controls. In control EBs, the levels of the pluripotency maintenance genes (ie, Pou5f1 and Nanog) were markedly down-regulated by day 1, whereas the genes involved in the initial phase of gastrulation (ie, Brachyury, Mixl1, and Cdx1) were strongly up-regulated, indicating a swift initiation of the differentiation program within 1 day of aggregation culture. In contrast, EBs treated with fluoxetine (6 mM) exhibited a delay in differentiation, such that the pluripotency genes continued to be highly expressed at day 1 and the up-regulation of the initial gastrulation genes was less robust than control ( Figure 4A) . A delay in differentiation was also evident in the expression patterns of other genes, such as the regulators of caudal patterning and somite formation (ie, Wnt3a, Tbx6, Hes7, and Meox1). In these genes, the up-regulation towards the peak expression (on day 2 for Wnt3a, Tbx6, and Hes7, and on day 3 for Meox1) was diminished in fluoxetine-treated EBs compared with control EBs ( Figure 4A ). This delayed differentiation seemed specific to the mesodermal lineage since genes expressed in the neural lineage (ie, Sox2, Otx2, Hoxc6, and Pax3) were either elevated or largely unaffected by fluoxetine treatment ( Figure 4A ). These results suggest that fluoxetine treatment (6 mM) is detrimental for mesodermal differentiation but is neutral or even permissive for neural differentiation in P19C5 EBs.
Several major developmental signaling pathways, namely Wnt, Nodal, Fgf, Bmp, and retinoic acid (RA), regulate germ layer differentiation and body patterning during embryogenesis. These major pathways also control morphogenesis and gene expression in P19C5 EBs (Li and Marikawa, 2015) . To assess whether fluoxetine alters these major developmental signals to cause adverse effects, we compared the gene expression profiles in fluoxetine-treated EBs with the "disruption profiles" of these signaling pathways. The previous study (Li and Marikawa, 2015) showed that the expression patterns of Pou5f1, Nanog, and Brachyury were differentially affected by inhibition of each of the major signaling pathways at days 1 and 2, and therefore, may be used to identify which pathway is disrupted ( Figure 4B ). The impact of fluoxetine (6 mM) was most similar to that of XAV939 (5 mM), an inhibitor of the canonical Wnt signaling pathway ( Figure 4B ). However, 2 other signaling inhibitors (SB431542 [Nodal inhibitor] and PD173074 [Fgf inhibitor]) also caused a decrease in the day 1 expression of the early mesoderm gene Brachyury, similarly to the impact of fluoxetine. To assess whether these 3 signaling pathways-Wnt, Nodal, and Fgf-are linked to the molecular impact of fluoxetine, we examined the target genes of these pathways: Sp5 for canonical Wnt signaling, Nodal for Nodal signaling, and Spry2 for Fgf signaling. Fluoxetine treatment caused a reduction in the expression of Sp5 at day 1 but did not reduce Nodal or Spry2 expression ( Figure 4A ), suggesting that fluoxetine at 6 mM may be inhibiting canonical Wnt signaling during EB development to alter EB morphogenesis. Note that Brachyury is also known to be a direct target of canonical Wnt and vertical axes represent relative expression levels in arbitrary units. Graphs show average relative expression levels, and error bars represent SD (n ¼ 3). Red asterisks indicate statistically significant differences in the expression levels between control and fluoxetine (6 mM) at the same day of culture (p < .05; 2-sample t test). B, Comparisons of expression profiles for Pou5f1, Nanog, and Brachyury on days 1 and 2 between EBs treated with fluoxetine and EBs treated with pharmacological inhibitors of the major developmental signals. The disruption profiles for the WNT, NODAL, FGF, BMP, and retinoic acid (RA) signaling inhibitors are based on the previous study (Li and Marikawa, 2015) . Abbreviation: NS, No significant change. For interpretation of the references to colour in this figure, the reader is referred to the online version of this article. signaling in mouse embryos and embryonic stem cells (Arnold et al., 2000; Yamaguchi et al., 1999) , and hence the diminished expression of Brachyury in P19C5 EBs by fluoxetine treatment further supports a reduction in canonical Wnt signaling.
Fluoxetine Inhibits Canonical Wnt Signaling in P19C5 Cells
We tested whether fluoxetine inhibits canonical Wnt signaling using 2 luciferase reporter assays, both of which measure the transcriptional activation mediated by ß-Catenin (CTNNB1) as a readout of Wnt signaling activity ( Figure 5A ). The TOPFLASH signal (Korinek et al., 1997) was significantly reduced by fluoxetine at 6 mM or higher in a dose-dependent manner, whereas the negative control FOPFLASH (containing mutations in the TCFbinding sites) yielded low signals regardless of fluoxetine concentration ( Figure 5B) . Similarly, the L1CBD-G4DBD-dependent luciferase activity (Tamashiro et al., 2008) was significantly reduced by fluoxetine at 6 mM or higher ( Figure 5C ). In contrast, the activity of ARE-Luc, a reporter construct for Nodal/Activin signaling (Weisberg et al., 1998) , was not significantly reduced by fluoxetine or XAV939, whereas it was robustly repressed by SB431542 ( Figure 5D ). These results indicate that fluoxetine inhibits canonical Wnt signaling at the same concentrations that adversely affected EB morphogenesis.
The impact of the fluoxetine enantiomers and the other SERT inhibitors was also assessed using the luciferase assays to further clarify the relationship between Wnt inhibition and morphogenetic effects. Both R-fluoxetine and S-fluoxetine reduced the TOPFLASH signal in a dose-dependent manner ( Figure 5E ). S-fluoxetine appeared to be slightly less potent than R-fluoxetine, which corresponded to the observed impact on EB morphogenesis ( Figure 2C ). The TOPFLASH signal was not significantly reduced by citalopram, venlafaxine, or 5-HT at any of the concentrations tested ( Figure 5F ), suggesting that inhibition of SERT does not diminish canonical Wnt signaling. Overall, the inhibitory impact of the chemical exposures on canonical Wnt signaling was consistent with their adverse effects on EB morphogenesis.
Activation of Canonical Wnt Signaling Partially Alleviates the Adverse Effects of Fluoxetine
We then tested whether the adverse morphogenetic effects of fluoxetine can be rescued by forced activation of canonical Wnt signaling. CHIR99021 is a pharmacological inhibitor of GSK3 and is widely used to activate canonical Wnt signaling in various cell types ( Figure 5A ). In P19C5 cells, CHIR99021 increased the TOPFLASH signal in a dose-dependent manner in the presence of fluoxetine at the adverse effect concentrations (6 and 10 mM), indicating that CHIR99021 can overcome fluoxetine to activate canonical Wnt signaling ( Figure 6A ). However, high concentrations of CHIR99021 alone also adversely affected EB morphology. EBs treated with CHIR99021 at 1 mM or higher was rounder than control EBs, resulting in a significant reduction in EDI ( Figure 6B ). This finding suggests that excessive and ubiquitous activation of canonical Wnt signaling is also detrimental to proper axial morphogenesis. Therefore, a rescue experiment for fluoxetine needs to be executed using concentrations of CHIR99021 that are <1 mM to avoid overactivation of Wnt signaling.
EBs were treated with fluoxetine (6 mM) together with CHIR99021 at 0.1 or 0.3 mM, and EB morphology was assessed after 4 days of culture. When compared with fluoxetine alone, EBs treated with fluoxetine and CHIR99021 were more elongated ( Figure 6C ). Both 0.1 and 0.3 mM of CHIR99021 were able to significantly increase the EDI of fluoxetine-treated EBs, but the 0.1 mM treatment appeared to be more effective ( Figure 6D ). Although the extent of rescue was partial, this result supports that the inhibition of canonical Wnt signaling is responsible for the adverse morphogenetic effects of fluoxetine.
Trifluoromethylphenyl Moiety of Fluoxetine Is Essential in Causing the Adverse Effects of Fluoxetine
XAV939 is a pharmacological inhibitor of tankyrases (TNKS), which are negative regulators of AXIN, the rate-limiting component of the ß-Catenin destruction complex (Huang et al., 2009) (Figure 5A ). In examining the chemical structure of XAV939 and fluoxetine, we noticed that both molecules contain a trifluoromethylphenyl group (Figs. 7A and 7B ). Norfluoxetine, which had similar morphologic effects to its parent molecule, fluoxetine ( Figure 2C ), also contains a trifluoromethylphenyl group ( Figure 7A) . Because of the structural similarity, it is possible that fluoxetine may act similarly to XAV939 to inhibit canonical Wnt signaling and alter EB morphogenesis. To assess whether the trifluoromethylphenyl moiety in fluoxetine was necessary in causing its adverse impacts, we examined the effect of nisoxetine, a norepinephrine reuptake inhibitor (NRI). Nisoxetine is structurally similar to fluoxetine, except that a trifluoromethyl group on the aromatic ring in para position is absent and instead a methoxy group is in ortho position (Figs. 7A and 7B ). Nisoxetine did not adversely affect EB morphogenesis even at the highest concentration evaluated (20 mM; Figure 7C ). In addition, nisoxetine did not significantly inhibit canonical Wnt signaling, based on the TOPFLASH assay ( Figure 7D ). These results suggest that the trifluoromethylphenyl moiety in fluoxetine mediates its morphogenetic impact and its inhibitory effect on Wnt signaling.
Fluoxetine Diminishes Cell Proliferation Independently of Its Inhibitory Effects on Wnt Signaling or SERT
Despite the similarities in structure and inhibitory effect on canonical Wnt signaling, XAV939 and fluoxetine exhibit different impacts on EB morphogenesis. XAV939 (0.5-5 mM) causes a marked reduction in EDI without affecting area (Li and Marikawa, 2015) , whereas fluoxetine (6-10 mM) lowered both area and EDI (Figure 2A) . A reduction in EB area implicates that fluoxetine diminishes cell proliferation during the aggregation culture that induces cell differentiation. To assess whether Asterisks in (A, D) indicate statistically significant differences between the 2 groups indicated (p < .01; 2-sample t test). Scale bars in (B, C) ¼ 500 mm.
fluoxetine also affects proliferation of undifferentiated P19C5 cells, monolayer culture was treated with fluoxetine at various concentrations for 4 days, and the number of viable cells was evaluated, based on the amount of metabolic activity. When compared with the control, fluoxetine caused a dose-dependent decrease in the number of viable cells at 6 mM and higher ( Figure 8A ). Note that 6 mM of fluoxetine decreased the viable cell number by about 20%, which was comparable to the extent of reduction in EB area at the same concentration of fluoxetine ( Figure 2B ). Fluoxetine treatment at higher than 10 mM, which was detrimental to the survival of EBs, decreased the viable cell number by >95% in monolayer culture. This suggests that cytostatic effects of fluoxetine reduce EB growth.
R-fluoxetine, S-fluoxetine, and norfluoxetine also decreased the number of viable cells in monolayer culture in a dosedependent manner comparable to the effect of fluoxetine, although S-fluoxetine again appeared slightly less potent ( Figure 8A ). In contrast, the viable cell number was not markedly reduced by nisoxetine even at the highest concentration examined (20 mM; Figure 8A ), suggesting that the trifluoromethylphenyl moiety is essential for the cytostatic effect of fluoxetine. Importantly, XAV939 (up to 2.5 mM) did not reduce the number of viable cells, although it markedly suppressed the TOPFLASH signal ( Figure 8B ). Therefore, neither the inhibition of canonical Wnt signaling nor the possession of a trifluoromethylphenyl group was sufficient to diminish cell proliferation.
To confirm that inhibition of canonical Wnt signaling does not diminish cell proliferation of P19C5 cells, we examined the effects of IWP2, another pharmacological inhibitor of Wnt signaling. IWP2 is an inhibitor of Porcupine, an acyltransferase that is required for the secretion of Wnt protein (Biechele et al., 2011; Chen et al., 2009) . Treatment of EBs with IWP2 reduced EDI in a dose-dependent manner (Figs. 8C and 8D) , similarly to the effects of XAV939 (Li and Marikawa, 2015) . IWP2 also substantially lowered the TOPFLASH signal in monolayer culture, indicating that IWP2 effectively inhibited canonical Wnt signaling ( Figure 8E) . However, the cell viability assay showed that IWP2 did not reduce the amount of metabolically active cells even at the highest concentration examined ( Figure 8F ). This result further supports the notion that inhibition of canonical Wnt signaling alone does not account for the cytostatic effect of fluoxetine.
Last, to test whether the action as an SSRI is linked to the cytostatic effect, the viable cell number in monolayer culture was assessed after exposure to citalopram, venlafaxine, or 5-HT ( Figure 8G ). None of these compounds significantly decreased viable cell numbers, suggesting that inhibition of SERT is not responsible for the cytostatic effect of fluoxetine.
DISCUSSION
In this study, we used the P19C5 EB morphogenesis model to investigate the developmental toxicity of fluoxetine, a common SSRI antidepressant that is often prescribed to women of reproductive age. EB morphogenesis was adversely affected by fluoxetine and norfluoxetine at 6 mM and above. Comparison to other serotonin reuptake inhibitors suggested that the adverse morphogenetic effects of fluoxetine were not mediated by SERT inhibition. Gene expression analyses in EBs showed that various developmental regulators were affected by fluoxetine; particularly those involved in mesodermal differentiation, and implied inhibition of canonical Wnt signaling. Signaling reporter assays confirmed that fluoxetine inhibits canonical Wnt signaling. Fluoxetine also exhibited cytostatic effects on P19C5 cells independently of its inhibition of SERT and Wnt signaling. We propose that the adverse morphogenetic impacts of fluoxetine reflect its effects on canonical Wnt signaling and cell proliferation rather than its therapeutic effects as a serotonin reuptake inhibitor (Figure 9 ). Considering the epidemiological findings linking maternal fluoxetine intake with an increased incidence of birth defects, this study provides mechanistic insight for further investigations into the safety of antidepressant use during pregnancy.
The findings of this study are only relevant if developing embryos in vivo are exposed to fluoxetine and norfluoxetine at the levels that cause adverse effects in EBs (ie, 6 mM or higher). A large multicenter study has shown that the mean plasma concentrations (6 SD) of fluoxetine, norfluoxetine, and a sum of the 2 in depressed patients are 0.31 6 0.16, 0.41 6 0.16, and 0.73 6 0.26 mM, respectively (Amsterdam et al., 1997) . Other studies involving depressed patients or healthy volunteers are also consistent with these plasma concentrations (Brunswick et al., 2002; Cheer and Goa, 2001; Teter et al., 2005) . As fluoxetine and norfluoxetine appear to cross the placental barrier readily, in utero concentrations may be comparable to the maternal plasma levels (Kim et al., 2004 (Kim et al., , 2006 . If that is the case, exposure levels to developing embryos on average (eg, 0.73 6 0.26 mM for a sum of fluoxetine and norfluoxetine) may be one order of magnitude lower than the concentrations that caused adverse morphogenetic effects in this study (ie, 6 mM of fluoxetine or norfluoxetine). However, fluoxetine and norfluoxetine exhibit tissue-specific accumulation, and their levels in the brain have been measured at concentrations 10-20 times higher than the plasma levels (Bolo et al., 2000; Karson et al., 1993) . Thus, it is important to determine whether similar accumulation occurs in the embryo or the reproductive tract. Furthermore, other conditions, such as hepatic impairment, intake of other medications that inhibit metabolizing enzymes, and accidental overdose, may significantly increase the plasma concentrations of fluoxetine and norfluoxetine (Cheer and Goa, 2001) . Therefore, although the average fluoxetine concentration during pregnancy may be below the adverse effect levels, many factors may temporarily increase exposure levels in certain individuals and contribute to the higher incidence of congenital malformations.
P19C5 EBs exhibit distinct temporal expression patterns of various developmental regulator genes over the 4 days of culture. Impact on the temporal expression profiles can provide mechanistic clues to investigate molecular actions of teratogens, as demonstrated in the previous study for valproic acid (Li and Marikawa, 2016) and in this study for fluoxetine. Although a handful of key regulators were evaluated in these studies, more global gene expression analyses, such as those employing the RNA-seq or microarray format, may enhance the sensitivity and applicability of the EB model to detect a wide range of teratogenic exposures. In addition, future studies may require alterations in the time frame of expression analyses in a genespecific manner. The current format uses daily sampling of EBs, ie, at days 1-4, and may not be able to capture the impact on gene expressions that change dynamically within a matter of hours. Relatively large error bars observed for some expression profiles in this study ( Figure 4A ) may be reflective of such insufficient temporal resolution to capture dynamic changes. Further investigations should reveal temporal expression behaviors of key gene expressions and help formulate more effective time points of analysis.
Fluoxetine inhibited canonical Wnt signaling in P19C5 cells. Although the exact mechanism by which fluoxetine interferes with Wnt signaling is unclear, the structural similarity to XAV939 raises the possibility that fluoxetine may act as an inhibitor of TNKS to stabilize AXIN ( Figure 5A ). Inhibition of canonical Wnt signaling by fluoxetine was also reported in a recent study using chondrogenic cells, in which the TOPFLASH signal and Wnt-mediated osteoarthritis-related phenotypes are attenuated by fluoxetine treatment (Miyamoto et al., 2017) . The concentrations of fluoxetine that inhibited Wnt signaling in these cells (eg, ! 5 mM to reduce the TOPFLASH signal) are comparable to the fluoxetine exposures (! 6 mM) that diminished Wnt signaling activity and altered EB morphology in this study. Miyamoto et al. (2017) also demonstrated enhanced binding of ß-Catenin (CTNNB1) to AXIN in cell lysate in the presence of fluoxetine, suggesting that fluoxetine may directly inhibit canonical Wnt signaling by stabilizing the association of ß-Catenin with the destruction complex. Conversely, another study using hippocampal neural precursor cells (NPCs) has reported that fluoxetine activates, rather than inhibits, canonical Wnt signaling, as evidenced by increases in nuclear ß-Catenin amount and the TOPFLASH signal (Hui et al., 2015) . Note, however, that the activation of canonical Wnt signaling in NPCs is induced by fluoxetine treatment at 1 mM, which is substantially lower than the levels that inhibited Wnt signaling in chondrogenic and P19C5 cells. Interestingly, the accumulation of nuclear ß-Catenin and Wnt-induced cell proliferation are attenuated in NPCs by cotreatment with WAY-100635, an antagonist of the 5-HT receptor, which implies that the activation of Wnt signaling is caused by the SSRI action of fluoxetine (Hui et al., 2015) . Thus, the apparent contradiction on how fluoxetine modulates Wnt signaling might be explained by the ability of NPCs to respond to the elevated 5-HT level caused by inhibition of SERT, which appears to be absent in P19C5 cells. If fluoxetine can directly act on the signaling components, such as TNKS, AXIN, and ß-Catenin, then higher concentrations of fluoxetine might inhibit canonical Wnt signaling in NPCs as well. Inhibition of canonical Wnt signaling may contribute to the etiology of birth defects associated with maternal fluoxetine intake, specifically cardiac malformations, such as ventricular septal defect (VSD), atrioventricular septal defect (AVSD), and right ventricular outflow tract obstruction (RVOTO) (Ellfolk and Malm, 2010; Gao et al., 2017; Reefhuis et al., 2015) . Genetic studies in mouse embryos have demonstrated that canonical Wnt signaling plays crucial roles in the development of the heart (Azhar and Ware, 2016; Gessert and Kü hl, 2010; Grigoryan et al., 2008; Ruiz-Villalba et al., 2016) . Functional ß-Catenin is required for the differentiation of cardiac progenitors (Lin et al. 2007) , the growth and diversification of the second heart field precursors into right ventricular and interventricular myocardium (Ai et al., 2007; Klaus et al., 2007; Kwon et al., 2007) , the migration of cardiac neural crest (Kioussi et al., 2002) , and the formation of the septum from the endocardial cushion (Azhar and Ware, 2016; Liebner et al., 2004) . Misregulation of these events during heart development may result in cardiac malformations, such as VSD, AVSD, and RVOTO (Lalani and Belmont, 2014) . Note, however, that these genetic studies are mainly based on the loss of ß-Catenin in specific embryonic tissues, which probably abolishes the activity of canonical Wnt signaling completely. In contrast, Wnt signaling inhibition by fluoxetine at 6-10 mM appeared to be more modest than the loss of ß-Catenin, judging from the extent of the TOPFLASH signal reduction ( Figure 5B ). Further investigations are warranted to understand how moderate inhibition of canonical Wnt signaling affects the developing heart. Regardless, fluoxetine has been shown to inhibit the differentiation of beating cardiomyocytes in mouse embryonic stem cells at the concentrations of 5 mM and above (Kusakawa et al., 2008) , suggesting that even moderate inhibition of canonical Wnt signaling is sufficient to impair the development of the heart. Note also that in various tissues, canonical Wnt signaling has been shown to interact with noncanonical Wnt signaling, the latter of which acts through the calcium and/or planar cell polarity pathways, rather than acting via the ß-catenin pathway (Widelitz, 2005) . Because components of noncanonical Wnt signaling also play pivotal roles in heart morphogenesis (Dawson et al., 2013; Gessert and Kü hl, 2010) , disturbance in canonical Wnt signaling may impact noncanonical Wnt signaling to impair normal heart development.
The reduction of EB growth caused by fluoxetine was likely due to its cytostatic activity independently of its inhibitory effects on SERT and canonical Wnt signaling. Fluoxetine diminishes cell proliferation and viability in a variety of cell types, including breast cancer cell lines (Bowie, 2015; Sun et al., 2015) , ovarian cancer cell lines (Lee et al., 2010) , neuroblastoma cell lines (Choi et al., 2017) , pheochromocytoma cells (Han and Lee, 2009 ), hippocampal cells (Post et al., 2000; Schaz et al., 2011) , and hypothalamic neuroprogenitor cells (Sousa-Ferreira et al., 2014) , at concentrations that correspond to the adverse effect levels in P19C5 cells. The negative impact of fluoxetine on cellular proliferation and/or survival has been hypothesized to occur via a number of molecular pathways, including induction of endoplasmic reticulum (ER) stress, generation of reactive oxygen species, activation of NF-jB, increased influx of extracellular calcium, and phosphorylation of mitogen-activated kinases (Choi et al., 2017; Lee et al., 2010; Post et al., 2000) . The antiproliferative effects of fluoxetine may not be mediated by inhibition of SERT in some cases. In the pheochromocytoma cell line, fluoxetine enhances the effect of a cytotoxic agent (1-methyl-4-phenylpyridinium), whereas another SERT inhibitor amitriptyline attenuates the cytotoxic effect (Han and Lee, 2009 ). In the human embryonic kidney cell line, the dose-response profiles of the anti-proliferative effects of fluoxetine are similar between unmanipulated cells (no SERT expression) and those with SERT overexpression (Schaz et al., 2011) . The mechanism by which fluoxetine interacts with the molecular pathways described above in an SERT-independent manner is still unclear. Nonetheless, it is of interest to investigate the involvement of these pathways in the fluoxetine-induced reduction in P9C5 EB growth and the inhibition of canonical Wnt signaling.
In addition to fluoxetine, various other types of SSRIs are frequently prescribed to reproductive-age women. Epidemiologic studies that compiled data for all SSRIs together as a single class indicate the absence of a significant association between maternal SSRI intake and the occurrence of birth defects (Ornoy and Koren, 2017) . However, fluoxetine may cause birth defects through mechanisms unrelated to its SSRI action, as suggested in this study. For this reason, it is crucial to investigate the developmental toxicity of individual medications with consideration for unexpected off-target effects. Currently, animal-based tests are the gold standard to assess the developmental toxicity of chemical compounds. However, animal experimentation is costly, labor-intensive, and it poses ethical issues concerning animal welfare, especially given the large number of compounds that need to be tested. In vitro assays, such as the P19C5 EB morphogenesis-based tests, may be effectively used to gain valuable information on dose-response relationships and molecular mechanisms for a number of compounds in a practical and ethical manner. Our ongoing investigation using P19C5 EBs suggests that a few others commonly prescribed SSRI antidepressants, notably paroxetine and sertraline; also have adverse effects on developmental processes with the potency similar to fluoxetine. On the other hand, this study showed that citalopram, another common SSRI, did not exhibit adverse effects on EBs even at 20 mM, which is about 80-to 260-fold higher than the average plasma concentrations in patients (Ji et al., 2014; Overø, 1982) . Tests like this are important because, with a better understanding of the properties of individual medications, physicians can choose the most appropriate options to treat depressed women while minimizing the risk of causing unnecessary birth defects in human babies.
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